Harrow announced it will begin marketing and selling Vigamox, a fluoroquinolone antibiotic eye drop for bacterial conjunctivitis, following completion of the product’s new drug application transfer.
According to a company press release, Harrow in January purchased exclusive U.S. commercial rights to Vigamox (moxifloxacin hydrochloride ophthalmic solution 0.5%), along with four other FDA-approved ophthalmic products, for $130 million.
“With an exceptional record of safety and efficacy, Vigamox is a well-known, reliable and trusted product by U.S. eye care professionals, many of whom